Purpose: Since the combination of cisplatin and docetaxel have demonstrated activity in squamous cell carcinomas of the lung and oesophagus before, promising results in recurrent metastatic head and neck cancer were expected. Patients and Methods: Between September 1998 and October 2000, 40 patients entered this trial, 38 of whom were evaluable. Six patients were previously untreated, 24 had surgery and/or radiotherapy and 13 had received chemoradiation and/or surgery. Therapy consisted of 75 mg/m2 docetaxel (1-hour infusion) and 75 mg/m2 cisplatin (90-min infusion) on day 1, repeated every three weeks for a maximum of 6 courses. All patients received corticosteroids routinely, 5-HT3-antagonists, and hydration. Results: The overall response rate was 52.5% (95% confidence interval, 36.1 to 68.5%) including 7 complete (17.5% complete response; CR) and 14 partial remissions (35% partial response; PR). The overall response rate in patients who had no prior treatment (n = 6) was 100%, including 3 CR and 3 PR. In patients who had prior surgery and/or radiotherapy (n = 21) an overall response rate of 42.8% was observed, including 2 CR and 7 PR; 8 patients (38.1%) had stable disease, while disease progressed in 3 (14.3%). Six of 13 patients (46.2%) who had prior chemoradiation ± surgery responded, including 2 CR (15.4%) and 4 PR (30.8%), no change was seen in 4 patients (30.8%) and tumour progressed in 2 (15.4%). The median response duration for all patients was 10 months (range, 3–20), the median overall survival was 11 months (range, 1–30). Myelosuppression was commonly observed; WHO grade 3 or 4 neutropenia occurred in 12 patients (30%) each, and was complicated by septicaemia in 5 cases. WHO grade 3 anaemia was observed in only 3 patients (7.5%). Severe non-hematologic toxicity except for alopecia was rarely observed, and included diarrhea in 2 (5%), nausea/vomiting in 2 patients (5%) and stomatitis in 1 patient (2.5%). Conclusion: Our data suggest that docetaxel and cisplatin in combination is an effective and fairly well tolerated regimen for the treatment of head and neck cancer with an excellent response rate in previously untreated patients.

1.
Schantz SP, Harrison LB, Forastiere A: Cancer of the head and neck; in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott, 2001, ch 30, pp 789–917.
2.
Everett E, Vokes EE, Ralph R, Weichselbaum RR, Scott M, Lippman SM, Hong WK: Head and neck cancer (review). N Engl J Med 1993;328:184–194.
3.
Forastiere A: Head and neck cancer: Overview of recent developments and future directions. Semin Oncol 2000;27:1–4.
4.
Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK: Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Current status and future directions. Sem Oncol 2000;27:25–33.
5.
Vokes EE, Athanasiadis I: Chemotherapy for squamous cell carcinoma: The future is now. Ann Oncol 1996;7:15–29.
6.
Aapro M, Rowinsky E: Docetaxel: Assessing a range of activity. Anti-Cancer Drugs 2001;12(suppl):S1–S3.
7.
Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997;48:353–374.
8.
Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR: Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;15:1672–1678.
9.
Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533–537.
10.
Posner MR: Docetaxel in squamous cell cancer of the head and neck. Anti-Cancer Drugs 2001;12(suppl):S21–S24.
11.
Colevas AD, Poster MR: Docetaxel in head and neck cancer. Am J Clin Oncol 1998;21:482–486.
12.
Green MR: The current status of docetaxel for advanced non-small cell lung cancer. Anti-Cancer Drugs 2001;12 (suppl):S11–S16.
13.
Specht L, Kornum Larsen S, Sand Hansen H: Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous cell carcinoma of the head and neck. Ann Oncol 2000;11:845–849.
14.
Schöffski P, Catimel G, Planting AST, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR: Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1999;10:119–122.
15.
Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 1981;147:207–214.
16.
Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346–353.
17.
Anderson JR, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 1982;38:407–416.
18.
Pignon JP, Bourhis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000;355:949–955.
19.
Forastiere A, Metch B, Schuller D: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A southwest oncology group study. J Clin Oncol 1992;10:1245–1251.
20.
Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Poster MR: A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous cell carcinoma of the head and neck. Ann Oncol 2000;11:535–539.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.